Format

Send to

Choose Destination
Neuropharmacology. 2012 Mar;62(3):1544-53. doi: 10.1016/j.neuropharm.2010.12.001. Epub 2010 Dec 13.

Cholinergic contributions to the cognitive symptoms of schizophrenia and the viability of cholinergic treatments.

Author information

1
Department of Psychology and Neuroscience Program, University of Michigan, 530 Church Street, 4032 East Hall, Ann Arbor, MI 48109, USA. msarter@umich.edu

Abstract

Effective treatment of the cognitive symptoms of schizophrenia has remained an elusive goal. Despite the intense focus on treatments acting at or via cholinergic mechanisms, little remains known about the dynamic cholinergic abnormalities that contribute to the manifestation of the cognitive symptoms in patients. Evidence from basic neuroscientific and psychopharmacological investigations assists in proposing detailed cholinergic mechanisms and treatment targets for enhancement of attentional performance. Dynamic, cognitive performance-dependent abnormalities in cholinergic activity have been observed in animal models of the disorder and serve to further refine such proposals. Finally, the potential usefulness of individual groups of cholinergic drugs and important issues concerning the interactions between pro-cholinergic and antipsychotic treatments are addressed. The limited evidence available from patient studies and animal models indicates pressing research needs in order to guide the development of cholinergic treatments of the cognitive symptoms of schizophrenia.

PMID:
21156184
PMCID:
PMC3920544
DOI:
10.1016/j.neuropharm.2010.12.001
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center